Objective: To compare clinical efficacy of 1% metformin and alendronate gel in adjunct to scaling and root planning (SRP) on clinical and biochemical parameters in patients having moderate localized chronic periodontitis.
Methodology: In this randomized open label clinical trial, 60 systemically healthy, males and females aged 30-50 year, diagnosed with localized moderate chronic periodontitis were enrolled from Bahria Dental College Hospital by convenient sampling technique. Duration of study was 6 months. Participants with deepest periodontal pocket depth (PPD), clinical attachment loss (CAL), plaque index (PI) and mean sulcular bleeding index (mSBI) were included whereas those with history of periodontal therapy and mouthwashes were excluded. Patients were divided randomly into two groups each group consisting of 30 patients. Group A received Metformin 1% gel and Group B received Alendronate 1% gel, both intra-pocket with SRP at day 0. Clinical parameters were evaluated at day 0, 45 and 90. TNFα was evaluated by Eliza at day 0 and 90. Statistical analysis was done using SPSS version 23.
Results: Group A showed the significant reduction in PPD and CAL compared to group B while PI and mSBI were found non-significant. TNFα was significantly reduced in group A at day 90.
Conclusion: We found that 1% Metformin gel produced more beneficial effects in adjunct to SRP on clinical and biochemical parameters in comparison to 1% Alendronate gel.
Key words: Alendronate, chronic periodontitis, gingival crevicular fluid, Metformin, TNF-α.